ahead of guidance afternoon, and everyone. quarter was first our per strong good $XXX.X pleased a and the It revenue quarter ranges. both of financial $X.XX earnings as Mike, you, XXXX. for total million overall, finished share discuss fiscal of Thank We're to Hologic's of results very
Global of our growth XXXX half in fiscal revenue efforts the that ago focusing on in our was and Diagnostics, after to and began first all results year. growth our build a our second which our several and installed positive to the double-digit R&D the efforts to building preannounced of on Health, create we the led large Diagnostics, earlier Breast in are new more U.S. core dramatically year. much posted leadership especially our In systems. we and output Health teams base to start businesses: of Health, Breast stream differentiated transform the by Molecular core years clinically the team we robust progress JPMorgan strengths, represent to of started before we of productivity in momentum As International constant products. quarter by strong market-leading, XD largest currency Mammography our Molecular reorganized our Genius accelerate performance conference, These continued They again Breast
been which have automated cleared been high-volume the as sexual health, to establish continue a consistent enabled breast-conserving Health sales. have we in to more such to surgery. to journey, in utilization segment boom-and-bust broadest drive an Specifically, as large in past forward. predictable demand Health broken or the model cycles the categories, Breast growth companies CE result and ability two just systems fully the launched Razor/Razorblade have by role to small enter And marked have that and enable with have as should Fusion Panther start better, our attractive reproductive space. business grown and system XXXX. of us strong run base calendar going on with FDA XX the since the these new In developed to partner molecular of that Two-thirds have greater new fuel systems Molecular the mid that Panther these Panther in more our growing we products platforms. menu or that Breast adjacent new tests to of market assay mammography introduced play growth and revenue market to patient's the service assays than us well help unique acquired now the We of and of combined is growth Together, our installed strategies consistent, and customers Diagnostics, led
extending We large, Health are also our and the making low where international are the shares strengths great United to to progress Diagnostics opportunities our States. in Breast markets are Molecular but compared
have foundations the carefully Over consistent the growth. very built last few reliable international years, and we and for deliberately
in X.X% XXXX. revenue a good blood we OUS discuss introduction, and are that excluding And off results our of currency, in of low expectations. performed now. quarter more or The in both businesses result, the basis reported grew rate first start first XXXX a and Focal a aesthetics at With our on Revenue XX.X% X.X% detail revenue. and quarter. As contributing Faxitron well $XX.X let's growth double-digit acquired to ahead to grew in XXXX a constant $XXX.X million million with well in
Blood divested see back you compared been X.X%, this you can a as If have as would growth recent Screening revenue still significant well improvement out that to from about business our quarters. contribution
the In and have Diagnostics. million of declined international mentioned posting Molecular Health as had terms as growth Health double-digit domestic And our by well, which rates another sales internationally improvements accelerated X.X% quarter, I the businesses international and products, recent $XXX.X were XX.X%. quarter Cynosure. our consecutive of of double-digit in businesses a in increase earlier, excluding sales legacy recording our robust Blood led exceptional eighth we the performed of period, Surgical broad-based franchises Breast Cynosure total years. Breast grew first made geography, still quarter also at of reflecting our and in international growth Screening well Molecular and Including
on results. divisional Now, me our revenue detail more some provide let
$X.X million typically the growth X.X% upside Breast excluding which from Global an and a imaging for itself what $X.X Focal much robust Breast, totaled a Health, grew increase has globally. million XX.X%. reestablished million as in in Health of in Let's biggest quarter, driver revenue with Interventional of company Faxitron Breast start generated soft important in the recently. breast and results our is business, our $XXX.X of seasonally sales division Even the
sales We Faxitron are represented by consecutive especially the pleased of the growth. and sales year-over-year U.S. of Focal, three-quarters excluding in global quarter, than the X% increased that quarter sixth in which almost accelerating more
discussed XX% division, Health JPMorgan, continuum represents while we been the sales, have a There focused domestic strategic been we have Aesthetics franchise several from of breast Breast a about some business this only have but which transformed growth to our overly healthcare. As aspects transformation. into global on at of quietly across capital steady diversified strategically
sales with mid-teens. prioritized have we international Health First, Breast growth was the expansion evident again this in quarter which
nice that in revenue sales gantry have and larger is Second, recurring we steadily source business, grew strengthened our than first a quarter. the of service
a have foothold was used we market to acquisitions productivity the Third, last R&D to over line revenue to conserving our tuck-in increased quarter, flows slightly complete expectations. our our breast of engine. posting internal strong Fourth, surgery. months, growth this and that adjacent of better six in than Faxitron Focal the in two well cash the have performed establish we
gantries proud the contributed to XD, basis Breast have XXX in new breast mammography share imaging performance team global continue results. the have product Overall, HD led our and base upgrades convert clinical quarter, to products. from majority differentiated time, growth upgrades, our are sales to to significantly which customers diversified provides of new revenue XX% of helping our quarter. sold. SmartCurve represented mammography as These to we drove of which growth for first XDimensions gain at through our together and XD Clarity our this us us new Health points a be new farm for better quarter, But traditional XD contributed to more growth products, about systems segmentation, Intelligent this existing XD market couldn't building These and sustainable better XD These growth Breast Health in begun helped same customer Breast now New systems by systems. Health clinically installed such business. we XD, new
We work differentiated two based built never on new it clinically complementary but to course, of stronger around than mammography systems, tuck-in is this been division a of have products Breast core and today, core our has acquisitions. more Health do, multiple
Before on, since fiscal starting me simplified reporting our new we're external mention we let we've a year move this, a little.
press revenue only first so these quarter $X.X prior small our the year were compared These about the are sales to in to $X.X imaging. period, Health, other the sales and Specifically, in small too in in we've added million Breast the eliminated line numbers matter. release million to
division. of with. driver Now very let's revenue to the in where we're growth which $XXX.X turn million diagnostics this Molecular increased X.X%, remains pleased
Internationally, care. into we in fourth our than consecutive this volumes said $XXX.X the periods As quarter, we benefited collaboratively XX.X%, the testing partnerships. already disease in have was key non-recurring quarters. single-digit player strong quarter, This reflects XXXX. grew customer we And better assay Molecular from grew for third shares accelerating exclude enjoy with a patient categories rate. grew that niche work leader in molecular better to a at market a transformed In royalty well Molecular the XX revenue recent testing quarter business time for still XXth customers as molecular broad-based double-digits of in at U.S., the first high million and diagnostics of in we the if high and transmitted the how sexually you although JPMorgan, sales to well with drive
are we two extensions last largest and were based of contract As of system. that these our Panther growth the automated evidence customers our leveraged now complete. as fully we Molecular this, quarter quarter both we broad was in announced finalizing with multi-year
Trichomonas in the as viral was and the sales assays driven quantitative for encouraging markets We continue many consolidate to health Chlamydia assays HPV testing women's on our revenue legacy the Gonorrhea. more as In by place and have specifically, more increased by tests world. And quarter customers and around first utilization strong capabilities growth new we drive of well load Panthers development for to system.
assay demonstrated in last again space just our week, first-of-its-kind clearance to example, bacteria a called FDA the Genitalium. for an transmitted by new disease a we infectious M announcing For sexually innovative detect leadership
sales declined sales of shares sales cytology market due to due our the longer Moving declined remains mentioning cervical shift growth testing the $XXX.X ordering United perinatal high intervals. quarter. X.X% in were and significantly flat challenged It's basically patterns. to in in States, million first market on, a cytology while and the In worth that cancer cytology perinatal
in than business plays key diagnostics, out assays to related than little of it blood run strength screening last collection million, women's for our However, several ThinPrep our Elsewhere health expected revenue a year. $XX.X divested more remains the given molecular vial. higher a of ability us its to was the and role in core at
a As low-margin agreements with services revenue and Grifols. transition have products we reminder, reflects under this mainly
sales Surgical GYN recent represents high execution hysteroscope. mid-single-digit revenue, grew on trends NovaSure and were which Surgical at cover increasing XXXX X.X%. believe million and will We gears Fluent contributions with improve improving quarter, a where States shift course declined management our of Omni let's now fluid a the in new rate. than Surgical, little the based such sales from consistent products more while in growth grew MyoSure, of a and $XXX.X rate at over Now half the as single-digit United of system sales rates quarters. Surgical
Now, declined negatively let's and reduction as revenue to affected disappointing in $XX.X lasers turn PAC consumable than of decline category where keys. consolidated well This million of as sales fat represented SculpSure competition Aesthetics from non-evasive factors; first, result. Medical XX.X% two less increased primary a resulted sales XX% the of
body revenue than As our subcategory more by a declined in XX%. result,
certain following not procedures. the Second, health cautionary FDA's the on recovered letters women's has market
As sales of our quarter than of other skin-related in contrast, a sales In XX%. performed the more products health increasing XX%. well products result, women's and about declined
constant that pockets an to in good up is continues have that we exhibits of clear salesforce this demands. speed now attractive market at aesthetics overall. what have some to buzz with more generate It's ahead come the to market also that still we that performance work So, Cynosure a growth commercial
grew developing are such These customer our systems end and as can new approaches that rapid We cycles. developed new this include seeking attention of marketing skeletal toward sales TempSure the out internally as Surgical attract product briefly comparable $XX.X out To in million revenue products also in-licensed X.X% context the prior especially as weak of year well against the States. a very round products. capability United discussion outside
comps in in Given can the cause large changes growth rates. swings ordering small small patterns revenue base here relatively percentage or
Health, in by Breast Global quarter, good we to in financial largest strength So, first businesses; posted Molecular results the very our driven Diagnostics. International, and wrap-up,
in especially We Molecular are leveraging by accelerate Breast strengths to further working core growth Diagnostics. and Health our
We in and we Karleen are a off a result guidance as discuss for increasing that to XXXX are a good moment. the our guidance start in will year.
call over the let turn to me So, now her.
